Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to Cytochrome P450 2D6 genotype: Data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects

Clinical Therapeutics

Volumn 32, Issue 4, 2010, Pages 659-666

  Lim, Kyoung Soo ^a,b   Jang, In Jin ^a   Kim, Bo Hyung ^a   Kim, JaeWoo ^a   Jeon, Ji Young ^a   Tae, You Me ^a   Yi, SoJeong ^a   Eum, SoYoung ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Armed Forces Medical Research Institute   (South Korea)

Author keywords

CYP2D6; Drug interaction; Flecainide; Paroxetine; QT QTc

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 2D6; FLECAINIDE ACETATE; PAROXETINE;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DROWSINESS; DRUG METABOLISM; ELECTROCARDIOGRAM; ENZYME POLYMORPHISM; FATIGUE; FOLLOW UP; GENOTYPE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARTIAL LEAST SQUARES REGRESSION; QRS COMPLEX; QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; YAWNING;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FLECAINIDE; GENOTYPE; HUMANS; KOREA; MALE; PAROXETINE;

EID: 77952525813     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.04.002     Document Type: Article

References (21)

1. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs., Accessed March 22, 2010. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucml29357.pdf.
2. Morganroth J Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007, 81:108-113.
3. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004, 15:475-495. for the Independent Academic Task Force.
4. Glassman AH, Bigger JT Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001, 158:1774-1782.
5. Yap YG, Camm AJ Drug induced QT prolongation and torsades de pointes. Heart 2003, 89:1363-1372.
6. Gross AS, Mikus G, Fischer C, et al. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 1989, 28:555-566.
7. Tambocor-flecainide acetate tablet. 3M Pharmaceuticals., Accessed March 22, 2010. http://www.dailymed.nlm.nih.gov/dallymed/drugInfo.cfm?id=1423.
8. Morganroth J, Horowitz LN Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984, 53:89B-94B.
9. Nogales Asensio JM, Moreno Sánchez N, Doncel Vecino LJ, et al. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity. Int J Cardiol 2007, 114:E65-E67.
10. Thevenin J, Da Costa A, Roche F, et al. Flecainide induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol 2003, 26:1907-1908.
11. Lim KS, Cho JY Jang IJ, et al. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D610 allele in healthy Korean subjects. Br J Clin Pharmacol 2008, 66:660-666.
12. Fosser C, Duczynski G, Agin M, et al. Comparison of manual and automated measurements of the QT interval in healthy volunteers: An analysis of five thorough QT studies. Clin Pharmacol Ther 2009, 86:503-506.
13. Malik M, Hnatkova K, Batchvarov V, et al. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004, 27:1659-1669.
14. Tyl B, Kabbaj M, Fassi B, et al. Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: Variability and sample size considerations. J Clin Pharmacol 2009, 49:905-915.
15. Davis JD, Hackman F, Layton G, et al. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 2008, 65(Suppl 1):68-75.
16. Padrini R, Piovan D, Busa M, et al. Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 1993, 53:59-64.
17. Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994, 55:256-269.
18. Antonelli D, Atar S, Freedberg NA, Rosenfeld T Torsade de pointes in patients on chronic amiodarone treatment: Contributing factors and drug interactions. Isr Med Assoc J 2005, 7:163-165.
19. Riera AR, Uchida AH, Ferreira C, et al. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Cardiol J 2008, 15:209-219.
20. Venkatakrishnan K, Obach RS In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005, 33:845-852.
21. Sarapa N, Francom SF, Azzam SM, et al. Detection of clinically significant QTc prolongation in phase studies in healthy participants: Comparison of 2 semiautomated QT measurement methods. J Clin Pharmacol 2009, 49:103-108.